One minute instead of four hours—and a target end date for treatment
In the long struggle against cancers that return and resist, medicine occasionally finds not just a new weapon but a more humane way to wield it. European regulators have recommended approval of a subcutaneous form of Roche's Lunsumio — a bispecific antibody that recruits the body's own immune cells to destroy follicular lymphoma — reducing treatment from hours of intravenous infusion to a single minute's injection. For the more than 110,000 people diagnosed with this relentless disease each year, and especially those for whom earlier treatments have already failed, the recommendation signals both clinical progress and a quieter dignity: the possibility of care that asks less of a life already under strain.
- Follicular lymphoma follows a cruel rhythm — it yields to treatment, then returns harder to defeat, leaving patients who have relapsed twice or more with vanishingly few options.
- The existing intravenous Lunsumio already produced striking results, with nearly three-quarters of patients achieving complete response and two-thirds of those remaining in remission after four years — but the two-to-four-hour infusion sessions imposed a heavy burden on already exhausted patients.
- The subcutaneous formulation collapses that infusion window to roughly one minute, preserving the same drug levels in the bloodstream and the same safety profile while freeing patients from prolonged clinic stays.
- Side effects remained manageable — injection-site reactions were common but mild, and cytokine release syndrome, though present in about 30 percent of patients, was largely low-grade and resolved within two days.
- If the European Commission grants final approval, Lunsumio would become the first third-line follicular lymphoma treatment to combine fixed-duration therapy with subcutaneous delivery — giving patients both a faster injection and a defined end date for treatment.
- Roche has already submitted data to the FDA and other global regulators, and is exploring the drug in combination therapies and other blood cancers, suggesting this recommendation is one milestone in a much longer journey.
On a September morning in Basel, Roche announced that the European Medicines Agency's key committee had recommended approval of a subcutaneous formulation of Lunsumio, its bispecific antibody for follicular lymphoma. Final confirmation from the European Commission is expected shortly.
Follicular lymphoma is the most common slow-growing form of non-Hodgkin lymphoma, diagnosed in more than 110,000 people each year. The disease follows a punishing pattern: it responds to initial treatment, then relapses, and each relapse makes the cancer harder to control. Patients who have already exhausted two or more lines of therapy face a shrinking horizon.
Lunsumio addresses this by turning the immune system against the cancer itself, binding simultaneously to CD20 proteins on malignant B cells and CD3 receptors on T cells, redirecting the body's own defenses to destroy the tumor. In the phase II trial underpinning this recommendation, 58.5 percent of patients achieved a complete response, and roughly two-thirds of those remained in remission four years later — a median complete response duration of nearly 21 months.
The more immediate innovation, however, is logistical. The intravenous version of Lunsumio requires two to four hours in a clinic infusion chair. The subcutaneous version takes approximately one minute. For patients already navigating the exhausting demands of cancer care, that compression of time translates into fewer disrupted workdays, fewer hours away from family, and the possibility of treatment in an outpatient setting rather than a hospital center.
Safety held steady across both delivery methods. Injection-site reactions occurred in about 60 percent of patients but were mild to moderate. Cytokine release syndrome appeared in roughly 30 percent, yet most cases were low-grade and cleared within two days. No new safety concerns emerged.
The treatment is also fixed-duration — lasting roughly six to twelve months depending on response — offering patients something rare in cancer care: a defined end point. Roche's Chief Medical Officer described the recommendation as an expansion of choice, and if approved, Lunsumio would be the first third-line follicular lymphoma therapy to combine subcutaneous administration with a finite treatment course. Data have already been submitted to the FDA and other regulators worldwide.
On a September morning in Basel, Roche announced that European regulators had endorsed a new way to deliver one of its most promising cancer drugs. The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a subcutaneous formulation of Lunsumio, a bispecific antibody designed to fight follicular lymphoma in patients whose disease has already resisted multiple rounds of treatment. The final sign-off from the European Commission is expected soon.
Follicular lymphoma is the most common slow-growing form of non-Hodgkin lymphoma, accounting for roughly one in five cases. More than 110,000 people are diagnosed with it each year worldwide. The disease typically responds well to initial treatment, but the pattern is relentless: remission followed by relapse, and with each relapse, the cancer becomes harder to kill. Patients who have already tried two or more standard therapies face a narrowing set of options, and early progression signals a poor long-term outlook.
Lunsumio works by engaging a patient's own immune system. The drug targets CD20 on the surface of cancer B cells and CD3 on T cells, essentially redirecting the body's T cells to recognize and destroy the malignant cells. It was the first drug of its kind to win approval, and the clinical results have been striking. In the phase II trial that led to this recommendation, nearly three-quarters of patients—58.5 percent—achieved a complete response. More remarkably, about two-thirds of those patients remained in remission after four years. The median duration of complete response stretched to 20.8 months.
But the real innovation here is not just the drug itself. It is how it is delivered. The intravenous version of Lunsumio requires patients to sit in a clinic chair for two to four hours while the drug drips into their veins. The subcutaneous formulation—a simple injection under the skin—takes about one minute. For patients already burdened by cancer and its treatment, that difference is not trivial. It means fewer hours lost to medical appointments, less disruption to work and family life, and the possibility of receiving care in an outpatient setting rather than a hospital infusion center.
The safety profile remained consistent between the two delivery methods. The most common side effect was injection-site reactions, occurring in about 60 percent of patients but limited to mild to moderate severity. Cytokine release syndrome—a potentially serious immune response—occurred in roughly 30 percent of patients, but the vast majority experienced only low-grade symptoms that resolved within two days. No unexpected safety signals emerged.
Another feature sets this treatment apart: it is designed to be fixed-duration. Rather than an indefinite commitment to ongoing therapy, patients receive Lunsumio for approximately six to twelve months, depending on how their disease responds. This means they have a target end date, a moment when treatment concludes and they enter a treatment-free period. For a patient accustomed to the open-ended nature of cancer care, that clarity carries weight.
Roche's Chief Medical Officer, Levi Garraway, framed the approval recommendation as an expansion of choice. If the European Commission signs off, Lunsumio would become the first treatment available for third-line or later follicular lymphoma that combines both fixed-duration therapy and subcutaneous administration. The company is also investigating the drug in combination with other medicines and in other blood cancers, suggesting the clinical development program is far from complete.
The recommendation is based on solid data from the GO29781 study, a phase I/II trial that tested both intravenous and subcutaneous versions. The subcutaneous formulation demonstrated pharmacokinetic non-inferiority—meaning it achieved comparable drug levels in the bloodstream—while offering the practical advantages of speed and convenience. The same dosing schedule applies; patients simply receive it differently. Data from this trial have already been submitted to the U.S. Food and Drug Administration and other health authorities worldwide, setting the stage for approvals beyond Europe.
Citas Notables
If approved, the subcutaneous formulation could help to expand the treatment options available, offering people a fixed-duration therapy with a faster treatment administration time.— Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development
La Conversación del Hearth Otra perspectiva de la historia
Why does the delivery method matter so much here? Isn't it just a different way to get the same drug into the body?
It sounds small, but for someone receiving cancer treatment, the difference between a one-minute injection and a four-hour infusion reshapes their entire relationship with the disease. You're talking about reclaiming time, reducing the visibility of illness in daily life, and making treatment something that fits into an afternoon rather than consuming an entire day.
And the remission rates—two-thirds of patients staying in remission after four years—how does that compare to what was available before?
This is the first fixed-duration, subcutaneously-administered option for patients who've already failed two or more prior therapies. At that stage of disease, you're dealing with cancer that has proven resistant. The durability of response here is genuinely significant. You're not just buying time; you're buying years.
What about the side effects? Cytokine release syndrome sounds serious.
It can be, but the data here is reassuring. Nearly 30 percent of patients experienced it, but almost all of those cases were low-grade—the kind of thing that resolves on its own within a couple of days. Only 2 percent had grade 3 severity. The real burden was injection-site reactions, which are uncomfortable but manageable.
So this is primarily about quality of life, not about saving lives?
It's both. The efficacy is there—the remission rates are strong. But yes, much of the value lies in how treatment is delivered. When you're fighting a disease that will likely relapse again, giving patients back their time and autonomy matters profoundly. It changes what living with cancer actually feels like.
What happens next?
The European Commission makes the final call, likely soon. Meanwhile, the same data is in front of the FDA and other regulators worldwide. Roche is also exploring combinations with other drugs and applications in other blood cancers. This is probably just the beginning of what this molecule can do.